Sign In
Buy MOH
$200.34
+0.86 (+0.431%)
At Close: Jul 28, 2026
Ensign Group (ENSG) Down 5.1% Despite Q1 Earnings Beat
04:32pm, Friday, 06'th May 2022 Zacks Investment Research
Ensign Group's (ENSG) first-quarter results highlight sound contributions from the Skilled Services and Standard Bearer segments, partly offset by a rise in expenses mainly stemming from a higher cost
Medtronic (MDT) Global Business Gains Ground, Volume Woes Stay
03:11pm, Friday, 06'th May 2022 Zacks Investment Research
Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.
Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure
03:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
02:48pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
02:33pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
01:52pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
01:47pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
01:41pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.
4 Analysts Have This to Say About Molina Healthcare
07:04pm, Monday, 02'nd May 2022 Benzinga
Analysts have provided the following ratings for Molina Healthcare (NYSE:MOH) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
1
0
0
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
02:02pm, Monday, 02'nd May 2022 Zacks Investment Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
12:34pm, Monday, 02'nd May 2022 Zacks Investment Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
12:36pm, Friday, 29'th Apr 2022 Zacks Investment Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
12:47pm, Thursday, 28'th Apr 2022
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Molina Healthcare's (MOH) CEO Joe Zubretsky on Q1 2022 Results - Earnings Call Transcript
12:40pm, Thursday, 28'th Apr 2022
Molina Healthcare, Inc. (NYSE:MOH ) Q1 2022 Earnings Conference Call April 27, 2022 8:00 AM ET Company Participants Joe Krocheski – Senior Vice President-Investor Relations Joe Zubretsky – Preside
Molina (MOH) Q1 Earnings and Revenues Top Estimates
09:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
